Immunotherapy for Alzheimer's disease

Acta Biochimica et Biophysica Sinica

Volumn 44, Issue 10, 2012, Pages 807-814

  Wang, Weihua ^a   Fan, Liangfeng ^a   Xu, De'En ^a,b   Wen, Zhongmin ^c   Yu, Rong ^d   Ma, Quanhong ^a  

^a SOOCHOW UNIVERSITY   (China)

^b WUXI NO 2 PEOPLE S HOSPITAL   (China)

^c THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^d SUZHOU MUNICIPAL HOSPITAL   (China)

Author keywords

amyloid; Alzheimer's disease; immunotherapy; tau; vaccine

Indexed keywords

AMYLOID BETA PROTEIN; ANTIBODY; TAU PROTEIN;

ALZHEIMER DISEASE; BRAIN; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; HUMAN; IMMUNIZATION; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; MICROGLIA; PATHOLOGY; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIBODIES; BRAIN; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNIZATION; IMMUNOTHERAPY; MICROGLIA; TAU PROTEINS;

EID: 84866975410     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gms065     Document Type: Review

References (76)

1. Kurz A and Perneczky R. Amyloid clearance as a treatment target against Alzheimer's disease. J Alzheimers Dis 2011, 24(Suppl. 2): 61-73.
2. Rowan MJ, Klyubin I, Wang Q, Hu NW and Anwyl R. Synaptic memory mechanisms: Alzheimer's disease amyloid beta-peptide-induced dysfunction. Biochem Soc Trans 2007, 35: 1219-1223. (Pubitemid 350206466)
3. Rapoport M, Dawson HN, Binder LI, Vitek MP and Ferreira A. Tau is essential to beta-amyloid-induced neurotoxicity. Proc Natl Acad Sci USA 2002, 99: 6364-6369.
4. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T and Gerstein H, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007, 316: 750-754. (Pubitemid 46717684)
5. Pritchard SM, Dolan PJ, Vitkus A and Johnson GV. The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics. J Cell Mol Med 2011, 15: 1621-1635.
6. Sardi SP, Murtie J, Koirala S, Patten BA and Corfas G. Presenilin-dependent ErbB4 nuclear signaling regulates the timing of astrogenesis in the developing brain. Cell 2006, 127: 185-197. (Pubitemid 44466644)
7. Gadadhar A, Marr R and Lazarov O. Presenilin-1 regulates neural progenitor cell differentiation in the adult brain. J Neurosci 2011, 31: 2615-2623.
8. Saura CA, Servian-Morilla E and Scholl FG. Presenilin/gamma-secretase regulates neurexin processing at synapses. PLoS One 2011, 6: e19430.
9. Auffret A, Mariani J and Rovira C. Age-related progressive synaptic dysfunction: the critical role of presenilin 1. Rev Neurosci 2010, 21: 239-250.
10. Hass MR, Sato C, Kopan R and Zhao G. Presenilin: RIP and beyond. Semin Cell Dev Biol 2009, 20: 201-210.
11. Hong L, Koelsch G, Lin X, Wu S, Terzyan S, Ghosh AK and Zhang XC, et al. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science 2000, 290: 150-153.
12. Citron M. Emerging Alzheimer's disease therapies: inhibition of betasecretase. Neurobiol Aging 2002, 23: 1017-1022. (Pubitemid 35447782)
13. Morgan D. Immunotherapy for Alzheimer's disease. J Intern Med 2011, 269: 54-63.
14. McGeer PL and McGeer EG. Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging 2001, 22: 799-809. (Pubitemid 34066546)
15. Wyss-Coray T, Yan F, Lin AH, Lambris JD, Alexander JJ, Quigg RJ and Masliah E. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci USA 2002, 99: 10837-10842.
16. Kitazawa M, Yamasaki TR and LaFerla FM. Microglia as a potential bridge between the amyloid beta-peptide and tau. Ann N Y Acad Sci 2004, 1035: 85-103. (Pubitemid 40362328)
17. Weiner HL and Frenkel D. Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol 2006, 6: 404-416.
18. Quinn J, Montine T, Morrow J, Woodward WR, Kulhanek D and Eckenstein F. Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease. J Neuroimmunol 2003, 137: 32-41. (Pubitemid 36351563)
19. Herber DL, Roth LM, Wilson D, Wilson N, Mason JE, Morgan D and Gordon MN. Time-dependent reduction in Abeta levels after intracranial LPS administration in APP transgenic mice. Exp Neurol 2004, 190: 245-253. (Pubitemid 39335723)
20. DiCarlo G, Wilcock D, Henderson D, Gordon M and Morgan D. Intrahippocampal LPS injections reduce Abeta load in APP + PS1 transgenic mice. Neurobiol Aging 2001, 22: 1007-1012. (Pubitemid 34066568)
21. Akiyama H and McGeer PL. Specificity of mechanisms for plaque removal after A beta immunotherapy for Alzheimer disease. Nat Med 2004, 10: 117-118; author reply 118-119.
22. Butovsky O, Talpalar AE, Ben-Yaakov K and Schwartz M. Activation of microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them protective. Mol Cell Neurosci 2005, 29: 381-393. (Pubitemid 40799211)
23. Gendelman HE. Neural immunity: Friend or foe? J Neurovirol 2002, 8: 474-479. (Pubitemid 36104714)
24. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H and Guido T, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000, 6: 916-919. (Pubitemid 30644751)
25. Wilcock DM, Munireddy SK, Rosenthal A, Ugen KE, Gordon MN and Morgan D. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis 2004, 15: 11-20. (Pubitemid 38134376)
26. Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D and Hyman BT. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci 2002, 22: 7873-7878. (Pubitemid 35379092)
27. Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE and Gordon MN, et al. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci 2003, 23: 3745-3751. (Pubitemid 36958481)
28. Solomon B, Koppel R, Frankel D and Hanan-Aharon E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci USA 1997, 94: 4109-4112. (Pubitemid 27180507)
29. Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V and Spooner ET, et al. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 2005, 11: 556-561. (Pubitemid 40685979)
30. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C and DeLong CA, et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 2002, 5: 452-457. (Pubitemid 34454251)
31. Baxter D. Active and passive immunity, vaccine types, excipients and licensing. Occup Med (Lond) 2007, 57: 552-556. (Pubitemid 350238115)
32. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T and Hu K, et al. Immunization with amyloid-beta attenuates Alzheimerdisease-like pathology in the PDAPP mouse. Nature 1999, 400: 173-177. (Pubitemid 29327547)
33. Das P, Murphy MP, Younkin LH, Younkin SG and Golde TE. Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging 2001, 22: 721-727. (Pubitemid 33055611)
34. Wilcock DM, Gordon MN, Ugen KE, Gottschall PE, DiCarlo G, Dickey C and Boyett KW, et al. Number of Abeta inoculations in APP + PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. DNA Cell Biol 2001, 20: 731-736. (Pubitemid 34072840)
35. Frenkel D, Kariv N and Solomon B. Generation of auto-antibodies towards Alzheimer's disease vaccination. Vaccine 2001, 19: 2615-2619. (Pubitemid 32234280)
36. Yankner BA, Duffy LK and Kirschner DA. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 1990, 250: 279-282.
37. Agadjanyan MG, Ghochikyan A, Petrushina I, Vasilevko V, Movsesyan N, Mkrtichyan M and Saing T, et al. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 2005, 174: 1580-1586.
38. Nemirovsky A, Fisher Y, Baron R, Cohen IR and Monsonego A. Amyloid beta-HSP60 peptide conjugate vaccine treats a mouse model of Alzheimer's disease. Vaccine 2011, 29: 4043-4050.
39. Movsesyan N, Ghochikyan A, Mkrtichyan M, Petrushina I, Davtyan H, Olkhanud PB and Head E, et al. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine-a novel immunotherapeutic strategy. PLoS One 2008, 3: e2124.
40. Frenkel D, Dewachter I, Van Leuven F and Solomon B. Reduction of beta-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization. Vaccine 2003, 21: 1060-1065. (Pubitemid 36139935)
41. Schneeberger A, Mandler M, Otawa O, Zauner W, Mattner F and Schmidt W. Development of AFFITOPE vaccines for Alzheimer's disease (AD)-from concept to clinical testing. J Nutr Health Aging 2009, 13: 264-267.
42. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC and Jouanny P, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003, 61: 46-54. (Pubitemid 36818745)
43. Cribbs DH, Ghochikyan A, Vasilevko V, Tran M, Petrushina I, Sadzikava N and Babikyan D, et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 2003, 15: 505-514. (Pubitemid 36432403)
44. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L and Koller M. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005, 64: 1563-1572. (Pubitemid 40617692)
45. Asuni AA, Boutajangout A, Scholtzova H, Knudsen E, Li YS, Quartermain D and Frangione B, et al. Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages. Eur J Neurosci 2006, 24: 2530-2542. (Pubitemid 44726765)
46. Head E, Pop V, Vasilevko V, Hill M, Saing T, Sarsoza F and Nistor M, et al. A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta. J Neurosci 2008, 28: 3555-3566.
47. Price KS and Hamilton RG. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc 2007, 28: 313-319.
48. Coors EA, Seybold H, Merk HF and Mahler V. Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. Ann Allergy Asthma Immunol 2005, 95: 593-599. (Pubitemid 43010488)
49. Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T and Maguire RP, et al. Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 2012, 11: 597-604.
50. Kutzler MA and Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet 2008, 9: 776-788.
51. Qu B, Rosenberg RN, Li L, Boyer PJ and Johnston SA. Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease. Arch Neurol 2004, 61: 1859-1864. (Pubitemid 39612946)
52. Lambracht-Washington D, Qu BX, Fu M, Eagar TN, Stuve O and Rosenberg RN. DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model. JAMA 2009, 302: 1796-1802.
53. DaSilva KA, Brown ME and McLaurin J. Reduced oligomeric and vascular amyloid-beta following immunization of TgCRND8 mice with an Alzheimer's DNA vaccine. Vaccine 2009, 27: 1365-1376.
54. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM and Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001, 98: 8850-8855. (Pubitemid 32678116)
55. DeMattos RB, Bales KR, Cummins DJ, Paul SM and Holtzman DM. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 2002, 295: 2264-2267. (Pubitemid 34258840)
56. Meyer-Luehmann M, Mora JR, Mielke M, Spires-Jones TL, de Calignon A, von Andrian UH and Hyman BT. T cell mediated cerebral hemorrhages and microhemorrhages during passive Abeta immunization in APPPS1 transgenic mice. Mol Neurodegener 2011, 6: 22.
57. Shah S and Federoff HJ. Therapeutic potential of vaccines for Alzheimer's disease. Immunotherapy 2011, 3: 287-298.
58. Morgan D. The role of microglia in antibody-mediated clearance of amyloid-beta from the brain. CNS Neurol Disord Drug Targets 2009, 8: 7-15.
59. Rabinovici GD and Jagust WJ. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol 2009, 21: 117-128.
60. Laskowitz DT and Kolls BJ. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2010, 74: 2026; author reply 2026-2027.
61. Blennow K, Zetterberg H, Wei J, Liu E, Black R and Grundman M. Immunotherapy with bapineuzumab lowers CSF tau protein levels in patients with Alzheimer's disease. Alzheimers Demen 2010, 6: S134-S135.
62. Samadi H and Sultzer D. Solanezumab for Alzheimer's disease. Expert Opin Biol Ther 2011, 11: 787-798.
63. Siemers ER, Friedrich S, Dean RA, Sethuraman G, DeMattos R, Jennings D and Tamagnan G, et al. Safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer's disease. Alzheimers Demen 2008, 4: T774.
64. Lemere CA and Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 2010, 6: 108-119.
65. Dodel RC, Du Y, Depboylu C, Hampel H, Frolich L, Haag A and Hemmeter U, et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004, 75: 1472-1474. (Pubitemid 39279821)
66. Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW and Younkin S, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009, 30: 1728-1736.
67. Maeda S, Sahara N, Saito Y, Murayama S, Ikai A and Takashima A. Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer's disease. Neurosci Res 2006, 54: 197-201. (Pubitemid 43276078)
68. Lasagna-Reeves CA, Castillo-Carranza DL, Jackson GR and Kayed R. Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies. Curr Alzheimer Res 2011, 8: 659-665.
69. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Clos AL, Jackson GR and Kayed R. Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol Neurodegener 2011, 6: 39.
70. Novak M. Tau transgenic rat model and response to tau vaccine. Alzheimers Demen 2010, 6: S118.
71. Asuni AA, Boutajangout A, Quartermain D and Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 2007, 27: 9115-9129. (Pubitemid 47312068)
72. Boutajangout A, Quartermain D and Sigurdsson EM. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 2010, 30: 16559-16566.
73. Rosenmann H, Grigoriadis N, Karussis D, Boimel M, Touloumi O, Ovadia H and Abramsky O. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol 2006, 63: 1459-1467. (Pubitemid 44547559)
74. Kayed R. Anti-tau oligomers passive vaccination for the treatment of Alzheimer disease. Hum Vaccin 2010, 6: 931-935.
75. Boutajangout A, Ingadottir J, Davies P and Sigurdsson EM. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 2011, 118: 658-667.
76. Krishnamurthy PK, Deng Y and Sigurdsson EM. Mechanistic studies of antibody-mediated clearance of Tau aggregates using an ex vivo brain slice model. Front Psychiatry 2011, 2: 59.